We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety and Immunogenicity of Glycoprotein D-- Adjuvant Genital Herpes Vaccine.
- Authors
Bernstein, David I.; Aoki, Fred Y.; Tyring, Stephen K.; Stanberry, Lawrence R.; St-Pierre, Claude; Shafran, Stephen D.; Leroux-Roels, Geert; Van Herck, Koen; Bollaerts, Anne; Dubin, Gary
- Abstract
Background. Two previous trials have suggested that a herpes simplex virus (HSV) type 2 glycoprotein D (gD) vaccine combined with the adjuvants alum and 3'-O-deacylated-monophosphoryl lipid A (MPL) is well tolerated and provides protection against genital herpes disease in women with no preexisting HSV antibody. Methods. The safety and immunogenicity of this vaccine were evaluated in a large, multicenter, double-blind, randomized, placebo-controlled trial. The effects of sex and preexisting HSV immunity were sought. Results. When solicited symptoms that continued after the initial 4 days of observation were excluded, the incidence of unsolicited symptoms occurring during the 7 months after vaccination (the primary analysis period) was 22.1% in vaccine recipients and 2 1.9% in placebo recipients. Significant increases in the number of local and systemic symptoms were found in vaccine recipients within 4 days after vaccination. However, most symptoms were mild to moderate in severity and were short lived. Women reported symptoms more frequently than did men, but preexisting immunity had little effect. The vaccine induced higher titers of HSV gD antibody on enzyme- linked immunosorbent assays than did natural infection with HSV. Conclusion. The vaccine was generally safe, well tolerated, and immunogenic.
- Subjects
HERPES genitalis; GLYCOPROTEINS; HERPES simplex virus; VACCINATION; HERPES simplex; SEXUALLY transmitted diseases
- Publication
Clinical Infectious Diseases, 2005, Vol 40, Issue 9, p1271
- ISSN
1058-4838
- Publication type
Article